Skip to main content
. 2018 Dec 12;24(4):563–569. doi: 10.1634/theoncologist.2018-0084

Table 1. Key baseline characteristics of patients in Cohort 1 of IMvigor210 and KEYNOTE‐052.

image

Data are presented as n (%).

a

Includes Karnofsky Performance Status <80% and visceral (lung, liver, or bone) metastases.

b

Proportion of PD‐L1‐stained tumor‐infiltrating immune cells within the tumor area.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; ICs, immune cells; MSKCC, Memorial Sloan Kettering Cancer Center; PD‐L1, programmed death‐ligand 1.